高级检索
    陆舜. KEYNOTE-024的5年生存数据:帕博利珠单抗单药对比化疗一线治疗PD-L1 TPS≥50%转移性非小细胞肺癌[J]. 循证医学, 2021, 21(4): 197-201. DOI: 10.12019/j.issn.1671-5144.2021.04.002
    引用本文: 陆舜. KEYNOTE-024的5年生存数据:帕博利珠单抗单药对比化疗一线治疗PD-L1 TPS≥50%转移性非小细胞肺癌[J]. 循证医学, 2021, 21(4): 197-201. DOI: 10.12019/j.issn.1671-5144.2021.04.002
    shu
    LU Shun. Five-Year Outcomes From KEYNOTE-024: Pembroli-zumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%[J]. Journal of Evidence-Based Medicine, 2021, 21(4): 197-201. DOI: 10.12019/j.issn.1671-5144.2021.04.002
    Citation: LU Shun. Five-Year Outcomes From KEYNOTE-024: Pembroli-zumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%[J]. Journal of Evidence-Based Medicine, 2021, 21(4): 197-201. DOI: 10.12019/j.issn.1671-5144.2021.04.002
    shu

    KEYNOTE-024的5年生存数据:帕博利珠单抗单药对比化疗一线治疗PD-L1 TPS≥50%转移性非小细胞肺癌

    Five-Year Outcomes From KEYNOTE-024: Pembroli-zumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%

      摘要
      • HTML全文
      • 参考文献(12)
      • 相关文章
      • 施引文献
    • 资源附件(0)

    /

    返回文章
    返回